1 Day CHGCF -16.80% DJIA 0.57% S&P 500 0.50% Health Care/Life Sciences 0.19% ...

The Soft Tissue Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the ...

Chugai obtains Japanese regulatory approval for Tecentriq for additional indication of alveolar soft part sarcoma, an ultra-rare disease: Tokyo Friday, February 21, 2025, 10:00 Hr ...

The wheels of the antibody-drug conjugate (ADC) juggernaut keep on turning, with Araris Biotech AG announcing a deal with a headline value of $780 million to apply its multi-payload linker technology ...

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Argenx (NASDAQ:ARGX) ADRs traded higher on Thursday premarket after Chugai (OTCPK:CHGCF) said that Enspryng, its Roche (OTCQX:RHHBY)-partnered experimental therapy for the autoimmune disorder ...

AstraZeneca has resolved a lingering liability following its takeover of Alexion with an agreement to pay $775 million to settle a patent dispute with Chugai Pharma, Roche's Japanese subsidiary.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...